公开(公告)号：US20240310385A1

公开(公告)日：2024-09-19

申请号：US18277838

申请日：2022-02-16

Applicant: Nightingale Health Oyj

Inventor： Heli Julkunen ,  Peter Würtz

IPC: G01N33/68 ,  G01N24/08 ,  G01N33/92

CPC classification number: G01N33/6893 ,  G01N24/08 ,  G01N33/92 ,  G01N2800/50

Abstract: A method for determining whether a subject is at risk of developing certain circulatory diseases is disclosed.

公开(公告)号：US20240302388A1

公开(公告)日：2024-09-12

申请号：US18275351

申请日：2022-02-01

Applicant: NIGHTINGALE HEALTH OYJ

Inventor： Heli Julkunen ,  Peter Würtz

IPC: G01N33/92 ,  G01N33/68

CPC classification number: G01N33/92 ,  G01N33/68 ,  G01N2333/4728 ,  G01N2405/00 ,  G01N2440/10 ,  G01N2800/52

Abstract: A method for determining whether a subject is at risk of dying from breast cancer or prostate cancer is disclosed.

公开(公告)号：US20240183862A1

公开(公告)日：2024-06-06

申请号：US18277861

申请日：2022-02-16

Applicant: Nightingale Health Oyj

Inventor： Heli Julkunen ,  Peter Würtz

IPC: G01N33/68 ,  G01N33/92

CPC classification number: G01N33/6893 ,  G01N33/6812 ,  G01N33/92 ,  G01N2800/06 ,  G01N2800/60

Abstract: A method for determining whether a subject is at risk of developing a digestive system disease is disclosed.

公开(公告)号：US20230243851A1

公开(公告)日：2023-08-03

申请号：US18011082

申请日：2021-06-18

Applicant: Nightingale Health Oyj

Inventor： Peter Würtz ,  Pasi Soininen ,  Antti J. Kangas ,  Kristian Nybo ,  Heli Julkunen ,  Anna Cichonska

IPC: G01N33/68 ,  G01N33/92

CPC classification number: G01N33/6893 ,  G01N33/92 ,  G01N33/6848 ,  G01N2800/26 ,  G01N2800/50 ,  G01N2800/042 ,  G01N2800/60

Abstract: A method for determining whether a subject has a disease or condition or is at risk of developing a disease or condition is disclosed. A method for determining whether a subject is at risk of developing an infectious disease or a complication thereof is also disclosed.

公开(公告)号：US20240036059A1

公开(公告)日：2024-02-01

申请号：US18039883

申请日：2021-12-02

Applicant: Nightingale Health Oyj

Inventor： Heli Julkunen ,  Peter Würtz

IPC: G01N33/68 ,  G01N24/08 ,  G01N33/92

CPC classification number: G01N33/6893 ,  G01N24/08 ,  G01N33/92 ,  G01N2800/04 ,  G01N2800/50

Abstract: A method for determining whether a subject is at risk of developing an anemia and/or a metabolic condition related to the nutritional state and/or fluid balance of the blood is disclosed.

公开(公告)号：US20230393158A1

公开(公告)日：2023-12-07

申请号：US18271573

申请日：2022-01-07

Applicant: Nightingale Health Oyj

Inventor： Peter Würtz ,  Heli Julkunen

IPC: G01N33/92 ,  G01N33/68 ,  G01N24/08

CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N24/08 ,  G01N2800/301 ,  G01N2800/50

Abstract: A method for determining whether a subject is at risk of developing a mental disorder; wherein the method comprises determining in a biological sample obtained from the subject a quantitative value of at lease one bio-marker of the following in the biological sample: glycoprotein acetyls, albumin, a ratio of docosahexaenoic acid to total fatty acids, a ratio of linoleic acid to total fatty acids, a ratio of monounsaturated fatty acids and/or of oleic acid to total fatty acids, a ratio of omega-3 fatty acids to total fatty acids, a ratio of omega-6 fatty acids to total fatty acids, a ratio of saturated fatty acids to total fatty acids, fatty acid degree of unsaturation, docosahexaenoic acid, linoleic acid, monounsaturated fatty acids and/or oleic acid, omega-3 fatty acids, omega-6 fatty acids, saturated fatty acids, triglycerides in high-density lipoprotein (HDL), triglycerides in low-density lipoprotein (LDL), high-density lipoprotein (HDL) particle size, low-density lipoprotein (LDL) particle size, very-low-density lipoprotein (VLDL) particle size, acetate, citrate, glutamine, histidine; and comparing the quantitative value(s) of the at least one biomarker to a control sample or to a control value; wherein an increase or a decrease in the quantitative value(s) of the at least one biomarker, when compared to the control sample or to the control value, is/are indicative of the subject having an increased risk of developing a mental disorder; wherein the at least one biomarker comprises or is glycoprotein acetyls, and wherein the mental disorder is anxiety disorder and/or reaction to severe stress disorder.